Structure Therapeutics Inc.GPCR
Metabolic5 cited findings · profile updated 2026-08-25
49.68 USDnot live — refreshed daily
About Structure Therapeutics Inc.
Structure Therapeutics Inc. is focused on metabolic therapeutic areas. The company is developing aleniglipron, which is currently in Phase 3 development within the ACCOMPLISH program. The ACCOMPLISH program includes two trials, ACCOMPLISH-1 and ACCOMPLISH-2, with enrollment numbers of 3,600 patients and 1,100 patients, respectively. In the aleniglipron ACCESS clinical trial OLE, a body weight reduction of 16.2% was observed. The aleniglipron ACCESS clinical trial also reported a discontinuation rate of 10.4%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Phase | 3 (aleniglipron ACCOMPLISH program) | Structure Therapeutics Inc. — SEC 8-K (2026-08-06), p.p.1 |
| Enrollment N | 3,600 patients (ACCOMPLISH-1) | Structure Therapeutics Inc. — SEC 8-K (2026-08-06), p.p.2 |
| Enrollment N | 1,100 patients (ACCOMPLISH-2) | Structure Therapeutics Inc. — SEC 8-K (2026-08-06), p.p.2 |
| body weight reduction | 16.2 % (aleniglipron ACCESS clinical trial OLE) | Structure Therapeutics Inc. — SEC 8-K (2026-08-06), p.p.2 |
| discontinuation rate | 10.4 % (aleniglipron ACCESS clinical trial) | Structure Therapeutics Inc. — SEC 8-K (2026-08-06), p.p.2 |
Key projects
- aleniglipron (metabolic)
aleniglipron is in Phase 3 development within the ACCOMPLISH program.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Metabolic research library →